Source: Annual Congress 2010 - Clinical issues in idiopathic pulmonary fibrosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Tcherakian, V. Cottin, P. Y. Brillet, J. F. Cordier, M. Brauner, D. Valeyre, H. Nunes (Bobigny, (Bron), France). Progression of idiopathic pulmonary fibrosis (IPF): Lessons from asymmetrical disease. Eur Respir J 2010; 36: Suppl. 54, 3627

Member's Comments

No comment yet.

Related content which might interest you: Disease progression in early idiopathic pulmonary fibrosis: Insights from the Australian IPF registry Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Idiopathic pulmonary fibrosis (IPF): the patient journey Source: Virtual Congress 2020 – Clinical aspects of idiopathic pulmonary fibrosis Year: 2020 Onset of symptoms in idiopathic pulmonary fibrosis: A case-control study Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2016 – Russia Session Year: 2016 Comparison between patients with idiopathic pulmonary fibrosis and patients with pulmonary involvement of the usual interstitial pneumonia pattern that preceded the onset of rheumatoid arthritis Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 PP217 – Modeling idiopathic pulmonary fibrosis on a lung-on-chip Source: ERS Lung Science Conference 2021 Year: 2021 Does emphysema coexistence with IPF change prognosis? Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Evaluating disease severity in idiopathic pulmonary fibrosis Source: Eur Respir Rev, 26 (145) 170051; 10.1183/16000617.0051-2017 Year: 2017 Plasma protein signature of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making Year: 2013 Patient journey to diagnosis of idiopathic pulmonary fibrosis (IPF) in the US Source: International Congress 2017 – ILDs: clinical aspects Year: 2017 Club cell secretory protein-CC16 is increased in idiopathic pulmonary fibrosis Source: International Congress 2016 – ILD pathogenesis Year: 2016 Idiopathic pulmonary fibrosis (IPF) Source: ERS Course 2016 Year: 2016 Role of midkine in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Clinical characteristics and survival in patients with idiopathic pulmonary fibrosis with and without associated emphysema Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Validation of GAP score in Danish patients diagnosed with idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 Non-pulmonary comorbidities in idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Real life experience with nintedanib in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Approach to diagnosis of idiopathic pulmonary fibrosis Source: International Congress 2016 – Russia Session Year: 2016